Peptides Hormones · Supplementary · from Peptides Hormones
Case 3: Insulin Resistance and Metabolic Optimization
Patient Presentation
Demographics: 46-year-old male entrepreneur
Chief Complaint: "My doctor says I'm pre-diabetic, but I don't want to just wait until I need medications. I want to fix this now."
History of Present Illness: The patient was found to have an HbA1c of 6.1% and fasting glucose of 112 mg/dL at his annual physical 3 months ago. His physician recommended lifestyle modifications and repeat testing in 6 months. Dissatisfied with the "wait and see" approach, he seeks a comprehensive metabolic optimization evaluation.
He reports a gradual 18 kg weight gain over 10 years, predominantly abdominal, now weighing 102 kg at 180 cm (BMI 31.5). He describes post-meal fatigue and "carb comas" after lunch, afternoon energy crashes requiring caffeine, and difficulty losing weight despite intermittent dieting attempts. He has noticed skin tags on his neck and axillae, and his wife has mentioned that the skin on the back of his neck appears darker.
He reports increased thirst and urination over the past year but attributed this to drinking more coffee. He snores loudly, and his wife reports observed apneas. He wakes unrefreshed despite 7-8 hours in bed. He has noticed declining cognitive sharpness, particularly in the afternoon, which concerns him as his business requires strategic decision-making.
Past Medical History:
- Pre-diabetes (recent diagnosis)
- Hypertension (borderline, not yet on medication)
- Non-alcoholic fatty liver disease (incidental finding on ultrasound 2 years ago)
- Gout (1 episode, 3 years ago)
Medications:
- None (declined metformin from PCP)
- Fish oil 1000 mg daily
- Multivitamin
Social History:
- Non-smoker, social alcohol (wine with dinner most nights, 10-14 units/week)
- Former college athlete (football), no current structured exercise
- High-stress business owner, works 50-60 hours/week
- Eats out frequently (business meals), large portions, high-carbohydrate diet
- Sleep: 7-8 hours in bed, unrefreshing, snoring
Family History:
- Father: Type 2 diabetes (diagnosed at 50, now on insulin), coronary artery disease
- Mother: Type 2 diabetes, obesity
- Paternal grandfather: Died of stroke at 62
- Two siblings: Both overweight, one with pre-diabetes
Physical Examination
- Vital Signs: BP 138/86 mmHg, HR 78 bpm, RR 14, Temp 36.8°C, SpO2 96% RA, BMI 31.5, Waist circumference 108 cm, Waist-to-hip ratio 1.02
- General: Obese male with central adiposity, appears well
- Skin: Acanthosis nigricans on posterior neck and bilateral axillae (Grade 2), multiple skin tags on neck (>10), no striae
- HEENT: Mallampati class III
- Cardiovascular: Regular rate and rhythm, S4 gallop heard at apex, no murmurs
- Abdomen: Obese, non-tender, liver edge palpable 2 cm below costal margin
- Extremities: No edema, no xanthomas
- Musculoskeletal: Decreased muscle mass relative to body habitus
Workup and Results
Laboratory Studies:
| Test | Result | Reference Range |
|---|---|---|
| Fasting glucose | 118 mg/dL | 70-100 mg/dL |
| Fasting insulin | 32.4 mU/L | 2.6-11.1 mU/L |
| HOMA-IR | 9.4 | < 1.7 (optimal) |
| HbA1c | 6.2% | < 5.7% (normal) |
| C-peptide (fasting) | 4.8 ng/mL | 0.8-3.1 ng/mL |
| 2-hour OGTT glucose | 186 mg/dL | < 140 normal, 140-199 IGT |
| 2-hour OGTT insulin | 248 mU/L | < 80 mU/L |
| Lipid panel | TC 232, LDL 142, HDL 32, TG 312 | TC <200, LDL <100, HDL >40, TG <150 |
| Apolipoprotein B | 148 mg/dL | < 90 mg/dL (optimal) |
| Lp(a) | 18 nmol/L | < 75 nmol/L |
| hs-CRP | 4.6 mg/L | < 1.0 mg/L optimal |
| Uric acid | 8.9 mg/dL | 3.5-7.2 mg/dL |
| AST | 52 U/L | < 40 U/L |
| ALT | 78 U/L | < 41 U/L |
| GGT | 92 U/L | < 60 U/L |
| Ferritin | 388 ng/mL | 12-300 ng/mL |
| HFE gene | Negative for C282Y and H63D | - |
| Adiponectin | 3.2 mcg/mL | 5-30 mcg/mL |
| Leptin | 42 ng/mL | 1-15 ng/mL (male) |
| Testosterone (total) | 312 ng/dL | 250-836 ng/dL |
| SHBG | 14 nmol/L | 10-57 nmol/L |
| Vitamin D | 24 ng/mL | 30-100 ng/mL |
Imaging/Additional Studies:
- Continuous glucose monitor (14-day data): Average glucose 128 mg/dL, time in range (70-140) 62%, glucose variability (CV) 32%, post-meal glucose peaks averaging 195 mg/dL with 60-minute time to peak
- FibroScan (liver elastography): CAP score 312 dB/m (steatosis grade S3, severe), liver stiffness 8.2 kPa (F2 fibrosis, moderate)
- Coronary artery calcium score: 82 Agatston units (above 75th percentile for age)
- Carotid intima-media thickness: 0.88 mm (elevated for age)
- Sleep study (home): AHI 22 events/hour (moderate OSA)
- DEXA body composition: Total body fat 38%, visceral adipose tissue area 182 cm2 (elevated), appendicular lean mass index borderline low
Clinical Image
Comprehensive diagram of the insulin resistance cascade showing the progression from visceral adiposity through hepatic steatosis, dyslipidemia, hyperinsulinemia, beta-cell exhaustion, and eventual type 2 diabetes, with interconnected pathways including inflammatory cytokines, adipokine imbalance, and cardiovascular risk amplification. Source: Educational illustration.
Diagnosis
Severe Insulin Resistance (HOMA-IR 9.4) with Impaired Glucose Tolerance, Metabolic Syndrome (5/5 criteria met), Non-Alcoholic Steatohepatitis (NASH) with Stage F2 Fibrosis, Moderate Obstructive Sleep Apnea, and Subclinical Atherosclerosis
Key Diagnostic Criteria:
- HOMA-IR 9.4 (severely insulin resistant; > 5.0 indicates marked resistance)
- Fasting hyperinsulinemia (32.4 mU/L) with elevated C-peptide indicating compensatory hyperinsulinemia
- Impaired glucose tolerance on OGTT (2-hour glucose 186 mg/dL) with massive insulin response (248 mU/L) demonstrating remaining but strained beta-cell capacity
- Metabolic syndrome (all 5 ATP III criteria): waist > 102 cm, TG > 150, HDL < 40, BP > 130/85, fasting glucose > 100
- NASH indicated by elevated transaminases with severe steatosis and F2 fibrosis on FibroScan
- Atherogenic dyslipidemia pattern: elevated TG, low HDL, elevated ApoB (small dense LDL pattern)
- Coronary artery calcium > 0 indicating established subclinical atherosclerosis
Treatment Plan
- Pharmacotherapy for metabolic optimization:
- Metformin 500 mg daily, titrate to 1000 mg BID over 4 weeks (insulin sensitization, hepatoprotective, reduces hepatic glucose output)
- GLP-1 receptor agonist: semaglutide 0.25 mg SC weekly, titrate to 1.0 mg weekly over 16 weeks (weight loss, cardiovascular risk reduction, potential NASH benefit)
- Consider pioglitazone 15-30 mg daily for NASH (evidence for fibrosis regression) after discussing risk profile
- Vitamin E 800 IU daily (evidence for NASH without diabetes, but limited in pre-diabetes; discuss with hepatologist)
- Cardiometabolic risk management:
- High-intensity statin: rosuvastatin 20 mg daily (CAC > 0 with elevated ApoB indicates treatment benefit regardless of LDL alone)
- Icosapent ethyl (Vascepa) 2 g BID for TG > 150 with elevated cardiovascular risk
- BP management: lisinopril 10 mg daily (target < 130/80 given metabolic syndrome)
- Dietary intervention (precision nutrition based on CGM data):
- Carbohydrate-controlled Mediterranean diet: 100-130 g carbohydrates/day, emphasizing low glycemic index sources
- Protein target: 1.6 g/kg ideal body weight/day (130 g/day) to support lean mass preservation
- Eliminate alcohol (directly contributes to hepatic steatosis, caloric excess, and uric acid elevation)
- Meal sequencing: vegetables and protein first, carbohydrates last (CGM-guided strategy shown to reduce glucose spikes by 30-40%)
- Time-restricted eating: 10-hour eating window (8 AM-6 PM)
- Exercise prescription:
- Resistance training 3-4x/week (large muscle groups, 8-12 reps, progressive overload) - resistance training improves insulin sensitivity via GLUT4 translocation independent of weight loss
- Zone 2 aerobic training 150 min/week (brisk walking, cycling) targeting 60-70% max HR
- Post-meal walks: 15-minute walk after each main meal (reduces post-prandial glucose by 20-30%)
- OSA treatment: CPAP with compliance monitoring; untreated OSA worsens insulin resistance via sympathetic activation and intermittent hypoxia
- CGM-guided optimization: Continue CGM for 3 months; target time in range > 85%, glucose variability CV < 25%, post-meal peaks < 140 mg/dL
- Peptide therapy consideration: Discuss potential role of tesamorelin (GHRH analog) for visceral fat and NASH given evidence for hepatic fat reduction in clinical trials; referral to endocrinologist for evaluation
- Monitoring: HbA1c, fasting insulin, lipid panel, and liver enzymes at 3 months; FibroScan at 12 months; CAC score repeat at 3-5 years; CGM review monthly for first 3 months
Key Learning Points
- HOMA-IR and fasting insulin are more sensitive early markers of metabolic dysfunction than fasting glucose or HbA1c alone; a patient can have severe insulin resistance and hyperinsulinemia for 5-10 years before glucose values become overtly diabetic
- Continuous glucose monitoring in non-diabetic patients provides actionable data on individual glycemic responses to foods, meal timing, exercise, and sleep that cannot be captured by standard lab testing
- NAFLD/NASH is the hepatic manifestation of insulin resistance and is now the leading cause of liver disease worldwide; FibroScan allows non-invasive staging, and F2 fibrosis represents a critical decision point for aggressive intervention
- Apolipoprotein B is superior to LDL-C for cardiovascular risk assessment in insulin-resistant patients because it captures atherogenic particle number including small dense LDL, VLDL remnants, and IDL that are characteristic of the metabolic syndrome lipid phenotype
- The combination of early pharmacotherapy (metformin + GLP-1 RA), structured exercise (especially resistance training), dietary carbohydrate optimization, and OSA treatment can reverse insulin resistance and potentially prevent progression to type 2 diabetes even with strong family history